Arcus Biosciences ((RCUS)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Arcus Biosciences is conducting a Phase 1 study titled ‘A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants With Gastrointestinal Malignancies.’ The study aims to assess the safety, tolerability, and clinical activity of AB680 in combination with other drugs in patients with advanced pancreatic cancer. This research is significant as it explores new treatment options for a challenging cancer type.
The study tests AB680, a CD73 inhibitor, in combination with zimberelimab, a monoclonal antibody targeting PD-1, and chemotherapy agents nab-paclitaxel and gemcitabine. These interventions are intended to enhance the treatment efficacy for pancreatic cancer.
This interventional study employs a randomized, sequential model with no masking, focusing on treatment. It includes a dose-escalation phase followed by dose-expansion cohorts to determine the optimal dosing and assess the treatment’s impact.
The study began on November 6, 2019, with the primary completion date yet to be determined. The latest update was submitted on June 25, 2025, indicating ongoing progress and adjustments in the study.
The study’s progress could influence Arcus Biosciences’ stock performance, as successful outcomes may boost investor confidence and market valuation. The competitive landscape in cancer treatment is intense, with many companies seeking breakthroughs, making this study’s results potentially impactful.
The study is ongoing, with further details available on the ClinicalTrials portal.